1-3 of 3
Cory Marvis
Close
Save search
Sort by
Journal Articles

Entinostat (SNDX-275), a Novel DAC Inhibitor, Is Highly Effective in Rituximab- [Chemotherapy]-Sensitive or Rituximab-[Chemotherapy]-Resistant Lymphomas and Has Synergistic Anti-Tumor Activity When Combined with Bortezomib.

Free
Umeer Ashraf, MD, Myron S. Czuczman, MD, Cory Marvis, MS, John Gibbs, MD, Francisco J Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2009) 114 (22): 3727.
https://doi.org/10.1182/blood.V114.22.3727.3727
Published: 2009
Journal Articles

Obatoclax and Bortezomib Therapy Results in Disruption of the p53-Mediated Apoptosis/Autophagy Pathway and Is Associated with Potent Synergistic Anti-Tumor Activity against Rituximab-Chemotherapy-Sensitive and -Resistant B-Cell Lymphoma.

Free
Francisco Hernandez-Ilizaliturri, MD, Ping-Chiao Tsio, MS, Ryan Campagna, BS, Cory Marvis, MS, Wasif Riaz, MD, Elizabeth Gruber, MS, John Gibbs, MD, Myron S. Czuczman, MD
Journal: Blood
Blood (2009) 114 (22): 288.
https://doi.org/10.1182/blood.V114.22.288.288
Published: 2009
Journal Articles

The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies.

Free
Francisco J Hernandez-Ilizaliturri, MD, Cory Marvis, MS, Ilir Maraj, MD, Mohammad M Chisti, MD, John Gibbs, MD, Myron S Czuczman
Journal: Blood
Blood (2009) 114 (22): 2715.
https://doi.org/10.1182/blood.V114.22.2715.2715
Published: 2009